The stock of Delivra Corp (CVE:DVA) gapped up by $0.01 today and has $0.62 target or 4.00% above today’s $0.60 share price. The 6 months technical chart setup indicates low risk for the $13.82M company. The gap was reported on Nov, 30 by Barchart.com. If the $0.62 price target is reached, the company will be worth $552,800 more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 327,506 shares traded hands or 1054.78% up from the average. Delivra Corp (CVE:DVA) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
More notable recent Delivra Corp (CVE:DVA) news were published by: Marketwired.com which released: “Delivra Corp. Issues $2020900, 6% Unsecured Convertible Debentures” on September 15, 2016, also Marketwired.com with their article: “Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis …” published on September 19, 2016, Marketwired.com published: “Delivra Announces Q2 2016 Financial Results” on August 29, 2016. More interesting news about Delivra Corp (CVE:DVA) were released by: Marketwired.com and their article: “Delivra Enhances Performance of Celebrex(TM) (Celecoxib) — New Formulation …” published on October 03, 2016 as well as Marketwired.com‘s news article titled: “Delivra Powers Diabetic Wound Healing” with publication date: March 29, 2016.
Delivra Corp., formerly Whiteknight Acquisitions III Inc., is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin. The company has a market cap of $13.82 million. The Firm makes and sells natural topical creams under its brand names, LivRelief, which is indicated for conditions, including joint and muscle pain, nerve pain, circulation and wound healing, and LivSport brand, which is indicated for sports performance. It currently has negative earnings. The Company’s business is divided into two areas of focus: Consumer Healthcare Over the Counter Retail products, and Technology Licensing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.